Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.60 |
| ▸ | PYGM | P11217 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465624 | 1.00 | TK1 (0.60) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL1027300 | 1.00 | TK1 (0.60) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL3415528 | 1.00 | TK1 (0.60) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL6314490 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL1129570 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL1130181 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL6753208 | 0.84 | SMN1; SMN2 (0.54) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL6760136 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL6752642 | 0.84 | LMNA (0.60) | TK1LMNASMN1; SMN2TSHRPMP22 | |
| SCHEMBL7701755 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157793-A1 | Modified nucleosides as antiviral agents | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2004-08-12 | — | — | US | claimed |
| WO-2004043402-A2 | MODIFIED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| EP-2604620-B9 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-2604620-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3521297-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, LTD. (BB) | 2019-10-17 | — | — | US | disclosed |
| EP-3521297-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3159351-A2 | MODIFIED 3'-AZIDO-4'-ETHYNYL-NUCLEOSIDES AS ANTIVIRAL AGENTS | Gilead Pharmasset LLC (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-1937825-B1 | MODIFIED 4'-NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD PHARMASSET LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9382286-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2004043402-A2 | MODIFIED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | EMORY UNIVERSITY | 2003-09-18 | — | — | US | disclosed |
| WO-2003053360-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD. (BB) | 2003-07-03 | — | — | WO | disclosed |
| US-20010018440-A1 | L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections | YALE UNIVERSITY AND THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-08-30 | — | — | US | disclosed |
| US-6274589-B1 | VIRICIDES TO TREAT EPSTEIN-BARR, VARICELLA-ZOSTER, AND/OR HERPES INFECTIONS; KAPOSI'S SARCOMA | YALE UNIVERSITY | 2001-08-14 | — | — | US | disclosed |
| US-6022876-A | KAPOSI'S SARCOMA; VARICELLA-ZOSTER VIRUS | YALE UNIVERSITY (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0956021-A1 | L-$g(b)-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5792773-A | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection | YALE UNIVERSITY (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1998020879-A1 | L-β-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | UMPS, UNG, TYMP | TK1 5/4885PYGM 1497/4885LMNA 2329/4885 |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | TK1 119/4885PYGM 1806/4885LMNA 1841/4885 |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | TK1 119/4885PYGM 1806/4885LMNA 1841/4885 |
| US-20040157793-A1 | Modified nucleosides as antiviral agents | PNP, SAMHD1, SLC29A1 | TK1 57/4885PYGM 1844/4885LMNA 1828/4885 |
| US-20010018440-A1 | L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections | UNG, DDX18, UMPS | TK1 30/4885PYGM 2159/4885LMNA 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.